Clinical trial readout dates for Regeneron Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 3 Dupilumab Atopic Dermatitis · NCT02612454 | October 2026 Primary data collected |
| Phase 3 Ravulizumab Paroxysmal Nocturnal Hemoglobinuria · NCT05133531 | September 2026 Primary data collected |
| Phase 3 mibavademab Generalized Lipodystrophy · NCT06548100 | July 2026 Primary data collected |
| Phase 2 Odronextamab B-cell Non-Hodgkin Lymphoma (B-NHL) · NCT03888105 | June 2026 Primary data collected |
| Phase 2 Trevogrumab-Part A Obesity · NCT06299098 | June 2026 Primary data collected |
| Phase 2 REGN7999 Non-Transfusion Dependent Beta-Thalassemia (NTDT) · NCT06421636 | December 2026 Ongoing |
| Phase 2 Alirocumab Hypercholesterolemia · NCT07477704 | December 2026 Ongoing |
| Phase 3 Fianlimab Melanoma · NCT05608291 | January 2027 Ongoing |
| Phase 2 REGN7508 Atrial Fibrillation (AF) · NCT07175428 | February 2027 Recruiting |
| Phase 3 REGN7508 Venous Thromboembolism (VTE) · NCT07015905 | February 2027 Recruiting |
These dates have elapsed; the company may have reported, or guidance may have shifted.
| Phase 2 cemiplimab Melanoma · NCT06190951 | November 2026 Ongoing |
| Phase 2 Olatorepatide Overweight or Obesity · NCT07431086 | November 2026 Ongoing |
| Phase 1/2 REGN7075 Advanced Solid Tumors · NCT04626635 | November 2026 Ongoing |
Regeneron Pharmaceuticals Inc. reported $18.68B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-30). It reported net income of $1.95B for that quarter.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-10-30 |